Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS EXP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Niguarda Hospital
ClinicalTrials.gov Identifier:
NCT00640367
First received: March 18, 2008
Last updated: April 24, 2014
Last verified: April 2014

March 18, 2008
April 24, 2014
February 2008
February 2009   (final data collection date for primary outcome measure)
To assess whether IA thrombolysis, as compared to IV rt-PA, increases survival free of disability (modified Rankin score of zero or 1) at 3 months. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
To assess whether local IA r-PA, as compared to IV rt-PA, increases survival free of disability (modified Rankin score of zero or 1) at 3 months. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00640367 on ClinicalTrials.gov Archive Site
To asses whether IA thrombolysis vs.IV rt-PA 1.improves the 7 day neurological deficit; 2.is safe on the base of symptomatic intracranial hemorrhages, fatal and non-fatal stroke, death from any cause, neurological deterioration within 7 days [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
1. IA rt-PA vs.IV rt-PA improves the 7 day neurological deficit. 2. IA rt-PA vs.IV rt-PA is safe on the base of symptomatic intracranial hemorrhages, fatal and non-fatal stroke, death from any cause, neurological deterioration within 7 days [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke
Synthesis Expansion: A Randomized Controlled Trial on Intra-Arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke

SYNTHESIS is a pragmatic multicenter randomized controlled trial (RCT), open-label, with blinded follow-up aiming to determine whether loco-regional intra-arterial (IA) with recombinant tissue-plasminogen activator (rt-PA) and/or mechanical devices, as compared with systemic intravenous (I.V.) infusion of rt-PA within 3 hours of ischemic stroke, increases the proportion of independent survivors at 3 months.

Eligibility criteria:patients with symptomatic, CT verified, acute ischemic stroke, being able to initiate IV rt-PA within 3 hours and IA thrombolysis within 6 hours of stroke onset, when uncertainty about appropriateness the two approaches exists as established by the treating physician.

Eligible patients are randomized to receive either 0.9 mg/kg (max 90 mg) IV rt-PA (control arm) or up to 0.9 mg/Kg IA rt-PA (max 90 mg) over 60 minutes into the thrombus, eventually associated with clot mechanical disaggregation/dislocation or retraction/aspiration. Mechanical thrombolysis is possible also without the use of rt-PA. The procedural choices of the interventional neuroradiologist depend on the type of occlusion, circumstances and experience.

The study is designed to detect or disprove (alpha=5% and power probability=80%) a 15% absolute difference between the treatment groups in the percentage of patients with a favourable outcome (Modified Rankin Scale Score = 0-1).Enrollment will be completed with 350 randomized patients.

Neurological deficit will be scored with NIH Stroke Scale at day 7 or discharge, or transfer to another hospital, whichever occurs first.Patient's clinical condition will be again evaluated by a telephone call after 90 days.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Stroke
  • Cerebrovascular Accident
  • Other: Alteplase IA and/or mechanical thrombolysis
    loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
  • Drug: Alteplase IV
    intravenous recombinant tissue plasminogen activator
  • Experimental: IA thrombolysis
    IA recombinant tissue plasminogen activator and/or mechanical thrombolysis
    Intervention: Other: Alteplase IA and/or mechanical thrombolysis
  • Active Comparator: IV rtPA
    IV recombinant tissue plasminogen activator
    Intervention: Drug: Alteplase IV
Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, Boccardi E; SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013 Mar 7;368(10):904-13. doi: 10.1056/NEJMoa1213701. Epub 2013 Feb 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
350
July 2012
February 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Sudden focal neurological deficit attributable to a stroke
  • Clearly defined time of onset, allowing initiation of intravenous treatment within 3 hours of symptoms onset and intra-arterial treatment within 6 hour of symptoms onset.
  • Age greater than 18 years

Exclusion Criteria:

  • Disability preceding stroke consistent with a modified Rankin scale score of 2-4
  • Coma at onset
  • Rapidly improving neurological deficit
  • Seizure at onset
  • Clinical presentation suggestive of a subarachnoid hemorrhage
  • Previous history of intracranial hemorrhage
  • Septic embolism
  • Arterial puncture at a non compressible site within the previous 7 days
  • Any traumatic brain injury within the previous 14 days
  • Surgery of the central nervous system in the previous 3 months
  • Gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 14 days.
  • Current therapy with intravenous or subcutaneous heparin to rise the clotting time
  • Known hereditary or acquired hemorrhagic diathesis, baseline INR greater than 1.5, aPTT more than 1.5 times normal, or baseline platelet count less than 100,000 per cubic millimeter
  • Baseline blood glucose concentrations below 2.75 mm/L (50 mg/dL).
  • Known contrast sensitivity.
  • Women of childbearing potential (unless pregnancy impossible) or known to be breastfeeding. Uncontrolled hypertension defined by a blood pressure greater or equal 185 mmHg systolic or diastolic greater or equal 110 mm Hg in 3 separate occasions at least 10 minutes apart or requiring continuous IV therapy.
  • Prognosis very poor regardless of therapy; likely to be dead within months.
  • Unlikely to be available for follow-up (eg, no fixed home address, visitor from overseas).
  • Any other condition which local investigators feels would pose a significant hazard in terms of risk/benefit to the patient, or if therapies are impracticable.

COMPUTED TOMOGRAPHIC (CT) SCAN EXCLUSION CRITERIA

  • Intracranial tumors except small meningioma
  • Hemorrhage of any degree
  • Acute infarction (since this may be an indicator that the time of onset is uncorrected)
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT00640367
SYNTHESIS EXPANSION
Yes
Niguarda Hospital
Niguarda Hospital
Not Provided
Principal Investigator: Alfonso Ciccone, MD A.O. Ospedale Niguarda Ca' Granda
Niguarda Hospital
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP